远大医药公布2025年中报:61.1亿港元营收再创新高 核药板块业绩持续爆发

环球网
Aug 19

8月19日,港股科技创新型医药企业远大医药发布2025年中期财报,上半年公司再度延续稳健发展态势,取得约61.1亿港元收入的历史新高,其中创新和壁垒产品收入占比约51%,同比提升近15个百分点,若剔除集采及汇率影响,公司收入同比增长约13%;期内公司净利润录得约11.7亿港元。根据公告,公司核药板块的易甘泰钇[90Y]微球注射液(易甘泰)、液体栓塞剂LavaTM,呼吸及危重症板块的恩卓润、恩明润、...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10